Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies

We investigated the medical and nursing records of 19 patients with unresectable advanced recurrent colorectal cancers treated using oxaliplatin and capecitabine(CapeOX)with or without bevacizumab at the outpatient tumor center of Showa UniversityHospital between November 1, 2009 and November 30, 20...

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 43; no. 8; p. 985
Main Authors:	Handa, Satoko, Kuroiwa, Ryohei, Miyano, Masahiro, Shimizu, Hisanori, Kamei, Daisuke, Takei, Hiromi, Sonou, Hiroko, Yamamoto, Hitomi, Murayama, JunIchiro, Sato, Atsushi, Kato, Yasuhisa
Format:	Journal Article
Language:	English Japanese
Published:	Japan 01-08-2016
Subjects:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Capecitabine - administration & dosage Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Female Humans Infusions, Intravenous - adverse effects Male Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Recurrence
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We investigated the medical and nursing records of 19 patients with unresectable advanced recurrent colorectal cancers treated using oxaliplatin and capecitabine(CapeOX)with or without bevacizumab at the outpatient tumor center of Showa UniversityHospital between November 1, 2009 and November 30, 2011, to clarifydifferences in the incidence of injection site reactions according to the use or non-use of an intravenous infusion solution warming device. Vascular pain and other injection site reactions occurred in 13 patients(68.4%). Injection site reactions occurred in 33 of the total of 77 chemotherapytreatments (42.9%). No difference in incidence of injection site reactions was seen according to whether the intravenous infusion solution warmer was used. The most common time to onset of injection site reactions after commencing oxaliplatin administration was 60-90 min, and symptoms were seen to decrease when non-steroidal anti-inflammatorydrugs were coadministered. We intend to leverage these studyfindings to demonstrate the mechanism of onset for injection site reactions and to propose measures for handling adverse drug reactions.
ISSN:	0385-0684